How Fast Does Zepbound Work? What the Trial Curves Show
A month-by-month look at tirzepatide's weight-loss curve from SURMOUNT-1 and the FDA label — when the dose is reached, when most of the loss happens, when people plateau, and what happens to late responders.
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.
Zepbound and Mounjaro are both tirzepatide — the same molecule, approved under two brand names for different uses. Zepbound is approved for weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity; Mounjaro is approved for type 2 diabetes [1].
Because tirzepatide is newer than semaglutide, its trial program reported some things the semaglutide program did not — including a formal analysis of when people plateau, and a follow-up of what happens to slow starters. That makes it possible to answer “how fast does Zepbound work” more precisely than for most drugs.
Everything below is a group average from a clinical trial. Nothing here is a dosing schedule. The FDA-approved labeling is the authority on how the product is used, and dose decisions belong to a prescriber.
About the label material on this page. Where this article describes dosing schedules, escalation, missed doses, storage or warnings, it is summarizing the FDA-approved prescribing information and Instructions for Use for Wegovy and Zepbound as published on DailyMed. Those documents are the authority, they are revised periodically, and they differ by product and by presentation (pen, prefilled syringe, single-dose vial, multi-dose vial). Follow the Instructions for Use that came with your own prescription, and take any question about your own dose, timing or supply to your prescriber or pharmacist rather than to this page.
What happens in the first few weeks?
In SURMOUNT-1, the pivotal weight-management trial, participants started at 2.5 mg and stepped up in four-week intervals: 2.5 to 5 mg, or through 2.5, 5 and 7.5 mg to reach 10 mg, or through 2.5, 5, 7.5, 10 and 12.5 mg to reach 15 mg [2]. The label describes an escalation period of up to 20 weeks followed by the maintenance period [1].
So the first month is one step on a ladder that has up to five rungs. The starting dose is chosen for tolerability, not for effect.
The label also says what the trial did alongside the drug: every participant received instruction on a reduced-calorie diet of roughly a 500 kcal/day deficit, counseling toward at least 150 minutes a week of physical activity, and behavior-modification counseling to help them stick to both, beginning with the first dose and continuing throughout [1]. The published results are results from that whole package.
Gastrointestinal symptoms tend to cluster around each step up. In SURMOUNT-1, 14.3% to 16.4% of people on tirzepatide discontinued the study drug overall, against 26.4% on placebo — meaning discontinuation was actually higher in the placebo group, most likely because it was not working [1].
Where does most of the weight loss happen?
This is the part tirzepatide’s trial program reported unusually well.
A post hoc analysis of SURMOUNT-1 found that percent weight reduction was greatest in the first 24 weeks and remarkably similar across starting BMI categories: mean change from baseline to week 24 was 13.4%, 14.5%, 14.3% and 13.3% for overweight, class I, class II and class III obesity respectively [3].
After week 24, the groups diverged. Between weeks 24 and 72, people with class I, II and III obesity lost an additional 7.0%, 8.8% and 9.7%, while people in the overweight category lost only 4.6% more [3].
That is a genuinely useful pattern to know in advance. Everyone loses at a similar rate in the first six months. Whether the loss keeps going after that depends heavily on how much there is to lose.
When do people plateau?
The same analysis set a formal definition: a plateau is a weight change of less than 5% across a 12-week interval and every subsequent 12-week interval. That is a research definition, not the feeling of a flat week on a bathroom scale.
Median time to plateau in SURMOUNT-1 [3]:
| Starting category | Median weeks to plateau |
|---|---|
| Overweight | 24.3 |
| Class I obesity | 26.0 |
| Class II obesity | 36.1 |
| Class III obesity | 36.1 |
By week 72, 90.2%, 88.9%, 87.6% and 87.8% of participants across those four categories had plateaued [3]. Higher doses (10 or 15 mg), younger age and female sex were each associated with reaching the plateau later — and a longer time to plateau went with greater total weight loss [3].
SURMOUNT-4, which used a 36-week open-label lead-in, produced similar results [3].
Put simply: somewhere between six and nine months is when most people on tirzepatide stop losing meaningfully. That is the expected shape of the curve, not a sign the drug has failed.
What if I have lost almost nothing at three months?
A separate SURMOUNT-1 post hoc analysis looked at 1,545 participants who received at least 75% of their assigned doses and split them by their week-12 result [4].
Eighteen percent had lost less than 5% at week 12 — “late responders.” They were more likely to be male (45% vs 30%) and started heavier (110.2 kg vs 103.6 kg, BMI 39.1 vs 37.7) [4].
Here is what happened to them:
- By week 24, 194 of 278 late responders (70%) had reached at least 5% weight reduction.
- By week 72, 250 of 278 (90%) had.
- The mean time for a late responder to reach 5% was 24.8 weeks [4].
The authors’ conclusion is worth quoting in spirit: extending treatment well beyond 12 weeks may allow additional patients to reach clinically meaningful weight reduction. A quiet first three months is common and is a poor predictor of where you end up.
What are the full-trial numbers?
From the Zepbound label, week 72, intention-to-treat [1]:
Study 1 (obesity or overweight, type 2 diabetes excluded)
| Placebo | 5 mg | 10 mg | 15 mg | |
|---|---|---|---|---|
| Mean weight change | -3.1% | -15.0% | -19.5% | -20.9% |
| Lost ≥5% | 34.5% | 85.1% | 88.9% | 90.9% |
| Lost ≥10% | 18.8% | 68.5% | 78.1% | 83.5% |
| Lost ≥15% | 8.8% | 48.0% | 66.6% | 70.6% |
| Lost ≥20% | 3.1% | 30.0% | 50.1% | 56.7% |
Study 2 (type 2 diabetes, BMI ≥27)
| Placebo | 10 mg | 15 mg | |
|---|---|---|---|
| Mean weight change | -3.2% | -12.8% | -14.7% |
| Lost ≥20% | 1.0% | 21.5% | 30.8% |
Under the company’s efficacy estimand — which models what happens if people stay on treatment — the SURMOUNT-1 figures were -16.0%, -21.4% and -22.5%, with 39.7% of the 15 mg group losing at least 25% [2]. Both sets of numbers are legitimate; they answer slightly different questions, and the label’s version is the more conservative one.
How does this compare with Wegovy?
SURMOUNT-5 was the first randomized head-to-head trial in adults with obesity without diabetes. Tirzepatide was superior to semaglutide for reduction in body weight and waist circumference at week 72 [5].
A 2026 systematic review and meta-analysis pooling 10 studies and 41,381 participants estimated tirzepatide produced 4.28 more percentage points of weight reduction (95% CI -5.28 to -3.28) and 4.43 kg more absolute loss. There was no difference at the 5% threshold, but higher odds of reaching 10%, 15% and 20%. Serious adverse events were more frequent with tirzepatide (relative risk 1.83), while overall and gastrointestinal adverse events and discontinuation for adverse events were similar [6].
A larger average does not tell you which drug will work better for any one person, and the trade-offs — cost, coverage, tolerability, supply — belong in a conversation with a prescriber.
What is coming off — fat or muscle?
A 160-participant DXA substudy of SURMOUNT-1 measured this directly. From baseline to week 72, tirzepatide produced -21.3% body weight, -33.9% fat mass and -10.9% lean mass, against -5.3%, -8.2% and -2.6% on placebo. Of the weight lost, approximately 74% was fat and 26% lean [7].
The number that matters most in that paragraph is the placebo comparison: the placebo group’s split was 75% fat and 25% lean — essentially identical. The proportion also held across sex, age group, dose and weight-loss tertile [7]. Visceral fat fell 40.1% and waist circumference 18.1 cm, versus 3.4 cm on placebo [7].
That does not make lean-mass loss irrelevant. It means the split looks like the split seen with other ways of losing this much weight, and that protein intake and resistance training are the levers, not the drug choice.
What happens if you stop?
SURMOUNT-4 was built to answer this. Seven hundred and eighty-three adults started an open-label 36-week lead-in on tirzepatide, titrated to a maximum tolerated dose of 10 or 15 mg; 14.4% discontinued before randomization, most often for adverse events. The 670 who remained had lost a mean 20.9% and were randomized to continue or switch to placebo for 52 weeks [1][8].
- Continuation group: lost a further 5.5%, reaching -25.3% from original baseline.
- Placebo-switch group: regained 14.0%, ending at -9.9% from baseline.
- Estimated treatment difference: -19.5 percentage points [8].
Two details are worth carrying away. First, the continuation arm did not plateau at week 36 — it kept losing, mostly between weeks 36 and 60. Second, 89.5% of people who continued maintained at least 80% of their lead-in weight loss at week 88, against 16.6% of those who switched [8].
A post hoc analysis published in JAMA Internal Medicine in 2026 found that 82.5% of people who stopped regained at least 25% of what they had lost within a year, and that improvements in waist circumference, systolic blood pressure, non-HDL cholesterol and HbA1c reversed in proportion to how much came back [9].
What do real people lose?
Less, on average, and mostly for reasons that have nothing to do with the molecule.
In a US health-system cohort of adults without diabetes, mean one-year weight reduction across everyone who started semaglutide or tirzepatide was 8.7% — 3.6% among people who stopped within three months, 6.8% with later discontinuation, and 11.9% among people who did not discontinue. Eighty-one percent were on low maintenance doses [10].
A separate two-system analysis put real-world tirzepatide total weight loss at 9.1% at one year on an intention-to-treat basis, rising to 11.7% among people with a full year of continuous orders [11].
The short version
- Escalation runs up to 20 weeks; the first month is one rung on the ladder.
- Most of the loss happens in the first 24 weeks, at a similar rate regardless of starting BMI.
- Median plateau is roughly 24 weeks for people with overweight and 36 weeks for class II or III obesity; by 72 weeks nearly 90% have plateaued.
- Slow at week 12 is common (18%) and mostly temporary — 90% of that group reached 5% by week 72.
- Label averages: -15.0%, -19.5% and -20.9% at 5, 10 and 15 mg over 72 weeks.
- Stopping reverses most of it, starting within about four weeks.
If your own curve does not look like these, that is information for a healthcare provider — not a reason to change anything yourself.
Sources
- Zepbound (tirzepatide) prescribing information, Eli Lilly, via DailyMed, revised August 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- Eli Lilly. SURMOUNT-1 results published in NEJM (investor release). https://investor.lilly.com/node/47371/pdf
- Horn DB et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity 2025. https://doi.org/10.1111/cob.12734
- Ard JD et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes Obes Metab 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12326891/
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). NEJM 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
- Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss: Systematic Review and Meta-Analysis. Clinical Obesity 2026. https://doi.org/10.1111/cob.70111
- Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11965027/
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2023. https://pubmed.ncbi.nlm.nih.gov/38078870/
- Horn DB et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity. JAMA Internal Medicine 2026;186(2):157. https://doi.org/10.1001/jamainternmed.2025.6112
- Gasoyan H et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity 2025. https://doi.org/10.1002/oby.24331
- Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity 2026. https://doi.org/10.1002/oby.70246
Questions people ask
How quickly does Zepbound start working?
Appetite changes often begin in the first weeks, but the dose escalation in SURMOUNT-1 ran up to 20 weeks before people reached their assigned maintenance dose. Most of the weight loss in that trial happened in the first 24 weeks, once the dose was climbing.
How much weight is lost in the first six months?
In a post hoc analysis of SURMOUNT-1, mean weight change from baseline to week 24 was about 13.3% to 14.5% depending on starting BMI category. Between weeks 24 and 72 an additional 4.6% to 9.7% came off, with the larger figures in people who started heavier.
When does Zepbound plateau?
Researchers defined a plateau as less than 5% weight change over a 12-week window and every window after it. Median time to plateau in SURMOUNT-1 was 24.3 weeks for people with overweight and 36.1 weeks for class II and class III obesity. By week 72, roughly 88-90% of participants in every BMI group had plateaued.
What if I have lost almost nothing by week 12?
In SURMOUNT-1, 18% of adherent participants lost less than 5% by week 12. By week 24, 70% of them had reached 5%; by week 72, 90% had. The average time for late responders to hit 5% was about 25 weeks. A slow first three months does not predict the final result well.
Does Zepbound work better than Wegovy?
In SURMOUNT-5, the first head-to-head randomized trial, tirzepatide produced greater weight and waist reduction than semaglutide at week 72. A 2026 meta-analysis of 10 studies and 41,381 participants estimated a 4.28 percentage-point advantage, with no difference at the 5% threshold but higher odds at 10%, 15% and 20%.
How much does the 15 mg dose add over 5 mg?
On the FDA label's accounting, mean week-72 weight change was -15.0% at 5 mg, -19.5% at 10 mg and -20.9% at 15 mg, against -3.1% on placebo. The 10 mg and 15 mg curves separated from each other later in the trial. Dose decisions belong to a prescriber.
Do results differ if you have type 2 diabetes?
Yes, consistently. In the label's diabetes trial, week-72 mean change was -12.8% at 10 mg and -14.7% at 15 mg, versus -19.5% and -20.9% in the trial that excluded diabetes.
What happens to the curve if you stop?
SURMOUNT-4 answered this directly. After a 36-week lead-in averaging -20.9%, people who continued lost a further 5.5% while those switched to placebo regained 14.0%. Weight started climbing within about four weeks of the switch.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.